A New Chapter in the Fight Against Hair Loss?

For millions of men, hair loss is more than a cosmetic concern. It can affect confidence, self-image and how comfortable someone feels about their appearance. Although several treatments already exist, finding an option that delivers satisfying results without unacceptable side effects remains a challenge.

Now, a pharmaceutical company called Veradermics has announced encouraging clinical trial results for an experimental hair-growth pill known as VDPHL01. The results have sparked discussion because the treatment demonstrated measurable improvements in hair count in a large study involving men with male pattern hair loss.

Some people have compared the excitement surrounding this development to the popularity of weight-management medications such as Ozempic. The comparison is about the possibility of a widely discussed treatment changing an established market, rather than the two medicines working in the same way.

But before declaring victory over baldness, there are several important details to understand.

What Exactly Is VDPHL01?

VDPHL01 is an investigational, extended-release oral formulation of minoxidil being developed by Veradermics for pattern hair loss.

Minoxidil is already a familiar name in hair-loss treatment. Certain topical minoxidil products are used to help treat pattern hair loss, while oral minoxidil has also been used by clinicians in selected circumstances. However, oral minoxidil is not the same as an FDA-approved hair-loss pill simply because the active ingredient has an established medical history.

Veradermics is developing VDPHL01 specifically as an oral treatment for pattern hair loss, with an extended-release formulation intended to provide a more controlled delivery of the medication.

The company's goal is to offer a treatment that can improve hair growth while maintaining an acceptable safety profile. That is particularly important because oral minoxidil can affect the cardiovascular system, making appropriate medical evaluation and monitoring essential.

VDPHL01 remains an investigational medicine. Its clinical results are encouraging, but its safety and effectiveness for routine use have not yet been established through FDA approval.

The 536-Man Clinical Trial: What Happened?

On October 19, 2026, Veradermics announced positive results from Study 304, a Phase 3 trial involving 536 men with mild-to-moderate pattern hair loss.

Participants were assigned to receive one of three options: an 8.5-milligram VDPHL01 regimen once daily, the same dose twice daily, or a placebo. A placebo is a comparison treatment that does not contain the active study medication.

The researchers assessed changes in non-vellus hair count, which focuses on thicker, more developed hairs rather than very fine, short hairs. They also examined participants' own reports of changes in hair coverage and other measures of improvement.

The results were encouraging. At the six-month assessment, the once-daily group recorded an average increase of 28.6 hairs per square centimetre in the target area. The twice-daily group recorded an average increase of 36.4 hairs per square centimetre.

For comparison, the placebo group recorded an average increase of 6.6 hairs per square centimetre.

These findings suggest that the treatment groups experienced greater increases in measured hair count than the placebo group. The company reported that the differences were statistically significant.

However, the figures describe averages across study groups. They do not mean every participant gained the same number of hairs, nor do they guarantee that an individual taking the medicine would experience a particular result.

Source: Veradermics' official Phase 3 results announcement.

Did Participants Really See Results After Two Months?

This is one of the most interesting parts of the announcement.

According to Veradermics, statistically significant differences from placebo were observed as early as the two-month assessment. This suggests that measurable improvements may begin relatively early during treatment.

However, the widely shared figure of 36.4 additional hairs per square centimetre was recorded at the six-month assessment, not after just two months.

That distinction matters because an early sign of improvement and the final measured result are two different things.

The trial also collected participants' reports about their hair coverage. After six months, 68.7% of participants in the twice-daily group reported that their coverage was improved or much improved. The corresponding figure was 55.7% in the once-daily group and 15% in the placebo group.

These findings provide another perspective beyond the hair-count measurements. Nevertheless, patient-reported improvement does not mean that every participant achieved complete regrowth or returned to their previous hairline.

Is VDPHL01 Already Approved by the FDA?

No. This is the most important qualification in the story.

Positive Phase 3 results are a major milestone in medicine development, but they do not automatically make a treatment available for general use.

The US Food and Drug Administration evaluates evidence from clinical studies, manufacturing information and other relevant safety and quality data before deciding whether a medicine can be approved for a particular use.

Veradermics has reported positive results from two registration-directed studies in men, involving more than 1,000 participants across the reported six-month trial results. That gives the company additional evidence to support its development programme.

However, the company's own pipeline information states that VDPHL01 has not been approved by the FDA or another regulatory authority.

The next steps will depend on the company's regulatory submissions, the evidence provided to regulators and the outcome of their review.

Until approval is granted, the treatment should not be described as an officially available, FDA-approved hair-loss pill.

What About Safety and Side Effects?

Positive hair-growth results are only part of the story. A treatment must also be evaluated for safety.

Veradermics reported that VDPHL01 was generally well tolerated during the six-month study period. The company said the trial recorded no treatment-related serious adverse events and no cardiac-origin adverse events of special interest.

Those findings are encouraging, but they do not prove that the treatment is risk-free. A clinical trial has limits, including its duration and the number of people studied. Additional monitoring can be important for identifying less common or longer-term risks.

The trial also reported hypertrichosis, a medical term for excessive hair growth, in 9% of participants in the twice-daily treatment group, compared with 2.2% in the once-daily group. This was an adverse event reported during treatment and is relevant when considering the overall balance of benefits and risks.

Oral minoxidil can also have effects involving blood pressure, fluid retention and heart rate. The risk for an individual depends on several factors, which is why medicines of this kind require professional medical assessment.

People should not try to obtain experimental treatments or change their medication based on headlines or social media posts. Anyone concerned about hair loss should speak with a qualified healthcare professional about suitable options.

Could This Change the Hair-Loss Treatment Market?

If VDPHL01 eventually receives approval and proves useful in routine medical practice, it could become another option for people experiencing pattern hair loss.

The potential appeal is straightforward: an oral treatment designed specifically for hair loss could offer an alternative to topical products for some patients, depending on the eventual approved label and medical advice.

However, the treatment will still need to demonstrate that its benefits, risks, convenience and cost make sense for patients. The final approved instructions, availability and pricing are not established by the Phase 3 results alone.

It is also worth remembering that hair loss has different causes. Male pattern hair loss is not the same as hair loss caused by nutritional deficiencies, certain illnesses, medications or other conditions. A treatment studied for one type of hair loss cannot automatically be assumed to work for every cause.

That is why a medical evaluation remains important rather than relying on a viral headline to determine what treatment is appropriate.

Final Verdict: A Promising Result, Not a Miracle Cure Yet

Veradermics' announcement is an encouraging development in hair-loss research. In a 536-man Phase 3 trial, VDPHL01 produced greater average hair-count increases than placebo, with statistically significant differences observed as early as month two and the largest reported figure of 36.4 additional hairs per square centimetre measured at six months in the twice-daily group.

Still, the medicine has not received FDA approval, and the results do not guarantee complete regrowth for everyone. Its eventual role will depend on regulatory review, further safety information and how well it performs in real-world use.

For now, the story is one of progress rather than a finished victory. If the treatment eventually receives approval, it could give clinicians another option for treating male pattern hair loss.

What do you think about this development? Could a new oral hair-loss treatment change the way people approach baldness? Share your thoughts in the comments, like this article if you found it useful, and follow the author for more health and science updates. If you want to support more independent writing, you can also consider donating.

Disclaimer: This article is for general information and is not medical advice. VDPHL01 remains investigational and has not been approved by the FDA. Always consult a qualified healthcare professional about hair loss and treatment options.